Atypical hemolytic-uremic syndrome

Atypical hemolytic-uremic syndrome is a disease that primarily affects kidney function. This condition, which can occur at any age, causes abnormal blood clots (thrombi) to form in small blood vessels in the kidneys. These clots can cause serious medical problems if they restrict or block blood flow. Atypical hemolytic-uremic syndrome is characterized by three major features related to abnormal clotting: hemolytic anemia, thrombocytopenia, and kidney failure.

Hemolytic anemia occurs when red blood cells break down (undergo hemolysis) prematurely. In atypical hemolytic-uremic syndrome, red blood cells can break apart as they squeeze past clots within small blood vessels. Anemia results if these cells are destroyed faster than the body can replace them. This condition can lead to unusually pale skin (pallor), yellowing of the eyes and skin (jaundice), fatigue, shortness of breath, and a rapid heart rate.

Thrombocytopenia is a reduced level of circulating platelets, which are cell fragments that normally assist with blood clotting. In people with atypical hemolytic-uremic syndrome, fewer platelets are available in the bloodstream because a large number of platelets are used to make abnormal clots. Thrombocytopenia can cause easy bruising and abnormal bleeding.

As a result of clot formation in small blood vessels, people with atypical hemolytic-uremic syndrome experience kidney damage and acute kidney failure that lead to end-stage renal disease (ESRD) in about half of all cases. These life-threatening complications prevent the kidneys from filtering fluids and waste products from the body effectively.

Atypical hemolytic-uremic syndrome should be distinguished from a more common condition called typical hemolytic-uremic syndrome. The two disorders have different causes and different signs and symptoms. Unlike the atypical form, the typical form is caused by infection with certain strains of Escherichia coli bacteria that produce toxic substances called Shiga-like toxins. The typical form is characterized by severe diarrhea and most often affects children younger than 10. The typical form is less likely than the atypical form to involve recurrent attacks of kidney damage that lead to ESRD.

Frequency

The incidence of atypical hemolytic-uremic syndrome is estimated to be 1 in 500,000 people per year in the United States. The atypical form is probably about 10 times less common than the typical form.
Causes

Atypical hemolytic-uremic syndrome often results from a combination of environmental and genetic factors. Mutations in at least seven genes appear to increase the risk of developing the disorder. Mutations in a gene called \textit{CFH} are most common; they have been found in about 30 percent of all cases of atypical hemolytic-uremic syndrome. Mutations in the other genes have each been identified in a smaller percentage of cases.

The genes associated with atypical hemolytic-uremic syndrome provide instructions for making proteins involved in a part of the body’s immune response known as the complement system. This system is a group of proteins that work together to destroy foreign invaders (such as bacteria and viruses), trigger inflammation, and remove debris from cells and tissues. The complement system must be carefully regulated so it targets only unwanted materials and does not attack the body’s healthy cells. The regulatory proteins associated with atypical hemolytic-uremic syndrome protect healthy cells by preventing activation of the complement system when it is not needed.

Mutations in the genes associated with atypical hemolytic-uremic syndrome lead to uncontrolled activation of the complement system. The overactive system attacks cells that line blood vessels in the kidneys, causing inflammation and the formation of abnormal clots. These abnormalities lead to kidney damage and, in many cases, kidney failure and ESRD.

Although gene mutations increase the risk of atypical hemolytic-uremic syndrome, studies suggest that they are often not sufficient to cause the disease. In people with certain genetic changes, the signs and symptoms of the disorder may be triggered by factors including certain medications (such as anticancer drugs), chronic diseases, viral or bacterial infections, cancers, organ transplantation, or pregnancy.

Some people with atypical hemolytic-uremic syndrome do not have any known genetic changes or environmental triggers for the disease. In these cases, the disorder is described as idiopathic.

Inheritance Pattern

Most cases of atypical hemolytic-uremic syndrome are sporadic, which means that they occur in people with no apparent history of the disorder in their family. Less than 20 percent of all cases have been reported to run in families. When the disorder is familial, it can have an autosomal dominant or an autosomal recessive pattern of inheritance.

Autosomal dominant inheritance means one copy of an altered gene in each cell is sufficient to increase the risk of the disorder. In some cases, an affected person inherits the mutation from one affected parent. However, most people with the autosomal dominant form of atypical hemolytic-uremic syndrome have no history of the disorder in their family. Because not everyone who inherits a gene mutation will develop the signs and symptoms of the disease, an affected individual may have unaffected relatives who carry a copy of the mutation.
Autosomal recessive inheritance means both copies of a gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

- aHUS
- non-Shiga-like toxin-associated HUS
- non-Stx-HUS
- nonenteropathic HUS

Diagnosis & Management

Genetic Testing Information

- What is genetic testing?
  https://primer/testing/genetictesting

Research Studies from ClinicalTrials.gov

- ClinicalTrials.gov https://clinicaltrials.gov/ct2/results?cond=%22atypical+hemolytic-uremic+syndrome%22+OR+%22Hemolytic-Uremic+Syndrome%22
Other Diagnosis and Management Resources

• GeneReview: Genetic Atypical Hemolytic-Uremic Syndrome  
  https://www.ncbi.nlm.nih.gov/books/NBK1367

• MedlinePlus Encyclopedia: Hemolytic Anemia  
  https://medlineplus.gov/ency/article/000571.htm

• MedlinePlus Encyclopedia: Hemolytic-Uremic Syndrome  
  https://medlineplus.gov/ency/article/000510.htm

• MedlinePlus Encyclopedia: Thrombocytopenia  
  https://medlineplus.gov/ency/article/000586.htm

• National Institute of Diabetes and Digestive and Kidney Diseases: Kidney Failure: Choosing a Treatment That's Right for You  

• National Organization for Rare Disorders (NORD) Physician’s Guide  

Additional Information & Resources

Health Information from MedlinePlus

• Encyclopedia: Hemolytic Anemia  
  https://medlineplus.gov/ency/article/000571.htm

• Encyclopedia: Hemolytic-Uremic Syndrome  
  https://medlineplus.gov/ency/article/000510.htm

• Encyclopedia: Thrombocytopenia  
  https://medlineplus.gov/ency/article/000586.htm

• Health Topic: Kidney Diseases  
  https://medlineplus.gov/kidneydiseases.html

• Health Topic: Platelet Disorders  
  https://medlineplus.gov/plateletdisorders.html

Genetic and Rare Diseases Information Center

• Atypical hemolytic uremic syndrome  
Additional NIH Resources

• National Heart, Lung, and Blood Institute: Hemolytic Anemia  
  https://www.nhlbi.nih.gov/health-topics/hemolytic-anemia

• National Heart, Lung, and Blood Institute: Thrombocytopenia  
  https://www.nhlbi.nih.gov/health-topics/thrombocytopenia

• National Institute of Diabetes and Digestive and Kidney Diseases: Kidney Failure: Choosing a Treatment That's Right for You  

Educational Resources

• MalaCards: genetic atypical hemolytic-uremic syndrome  
  https://www.malacards.org/card/genetic_atypical_hemolytic_uremic_symdrome

• Merck Manual Consumer Version: Overview of Anemia  
  https://www.merckmanuals.com/home/blood-disorders/anemia/overview-of-anemia

• Merck Manual Consumer Version: Thrombocytopenia  
  https://www.merckmanuals.com/home/blood-disorders/platelet-disorders/overview-of-thrombocytopenia

• Merck Manual Professional Version: Complement System  

• Orphanet: Atypical hemolytic-uremic syndrome  
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=2134

Patient Support and Advocacy Resources

• National Kidney Foundation  
  https://www.kidney.org/

• National Organization for Rare Disorders (NORD)  
  https://rarediseases.org/rare-diseases/atypical-hemolytic-uremic-syndrome/

• RareConnect  

• The Atypical HUS Foundation  
  https://www.ahus.org/

Clinical Information from GeneReviews

• Genetic Atypical Hemolytic-Uremic Syndrome  
  https://www.ncbi.nlm.nih.gov/books/NBK1367
Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28Hemolytic-Uremic+Syndrome%5BMJR%5D%29+AND+%28atypical+hemolytic-uremic+syndrome%5BTA%5D%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+720+days%22%5Bdp%5D

Catalog of Genes and Diseases from OMIM

- HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1
  http://omim.org/entry/235400

- HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 2
  http://omim.org/entry/612922

- HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 3
  http://omim.org/entry/612923

- HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 4
  http://omim.org/entry/612924

- HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 5
  http://omim.org/entry/612925

- HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 6
  http://omim.org/entry/612926

Medical Genetics Database from MedGen

- Atypical hemolytic uremic syndrome

Sources for This Summary


  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18594873
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20301541
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19846853
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15728781
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17599974
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20059470

Reprinted from Genetics Home Reference: 

Reviewed: June 2010
Published: March 12, 2019

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services